

# LABORATORIOS FARMACEUTICOS ROVI SA

ISIN: ES0157261019 WKN: - Asset Class: Stock

## Company

2024/05/02 17:41:06



Price  
**82.20**  
EUR

Difference ▲  
-2.49% (-2.10)



## Contact Details

LABORATORIOS FARMACEÚTICOS  
ROVI SA

Tel:  
+34-91-021-30-00

Fax:  
+34-91-304-78-81

--  
Calle José Isbert, 2, Pozuelo de Alarcón  
28223 Madrid

Web:  
<http://www.rovi.es>  
E-mail: [rovi@rovi.es](mailto:rovi@rovi.es)

## Company Profile

Laboratorios Farmaceuticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023        |                        | 2022        |                        | 2021        |                        |
|---------------------------------------|-------------|------------------------|-------------|------------------------|-------------|------------------------|
|                                       | Assets      | Liabilities and equity | Assets      | Liabilities and equity | Assets      | Liabilities and equity |
| <b>Current assets</b>                 | 511,124,000 |                        | 624,949,000 |                        | 510,108,000 |                        |
| <b>Common stock capital</b>           |             | 3,241,000              |             | 3,241,000              |             | 3,364,000              |
| <b>Fixed assets</b>                   | 288,760,000 |                        | 253,754,000 |                        | 222,568,000 |                        |
| <b>Equity capital of a company</b>    |             | 543,494,000            |             | 521,379,000            |             | 470,976,000            |
| <b>Cash and cash equivalents</b>      | 25,322,000  |                        | 124,945,000 |                        | 99,035,000  |                        |
| <b>Accrued liabilities</b>            |             | 0                      |             | 0                      |             | 0                      |
| <b>Other assets</b>                   | -           |                        | -           |                        | -           |                        |
| <b>Current liabilities</b>            |             | 200,461,000            |             | 293,928,000            |             | 190,406,000            |
| <b>Prepayments and accrued income</b> | -           |                        | -           |                        | -           |                        |
| <b>Non-current liabilities</b>        |             | 54,570,000             |             | 61,622,000             |             | 68,963,000             |
| <b>Different income</b>               |             | -                      |             | -                      |             | -                      |
| <b>Other liabilities</b>              |             | 1,431,000              |             | 1,545,000              |             | 1,460,000              |
| <b>Total assets</b>                   | 799,884,000 | 799,884,000            | 878,703,000 | 878,703,000            | 732,676,000 | 732,676,000            |

## Balance notes

|                            | 2023   | 2022   | 2021   |
|----------------------------|--------|--------|--------|
| <b>Accounting standard</b> | IFRS   | IFRS   | IFRS   |
| <b>Employees</b>           | 2,111  | 1,993  | 1,751  |
| <b>Equity ratio</b>        | 68.46% | 59.49% | 64.28% |
| <b>Debt-equity ratio</b>   | 46.07% | 68.09% | 55.57% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 22.72% | 22.62% | 16.20% |

# LABORATORIOS FARMACEUTICOS ROVI SA

ISIN: ES0157261019 WKN: - Asset Class: Stock

## Income statement

|  | 2023        | 2022        | 2021        |
|--|-------------|-------------|-------------|
| <b>Turnover</b>  | 829,509,000 | 817,698,000 | 648,677,000 |
| <b>Net income</b>  | 170,335,000 | 199,669,000 | 153,077,000 |
| <b>EBIT</b>  | 221,474,000 | 258,611,000 | 183,283,000 |
| <b>Operating income before taxes</b>                                 | 220,533,000 | 257,768,000 | 182,446,000 |
| <b>Cash Flow</b>   | 114,348,000 | 237,317,000 | 149,221,000 |
| <b>Net interest income</b>   | -941,000    | -843,000    | -837,000    |
| <b>Research and development expenses</b>                             | 24,923,000  | 23,869,000  | 27,445,000  |
| <b>Income taxes</b>  | 50,109,000  | 58,302,000  | 29,551,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | -125,000    | 199,000     | 182,000     |
| <b>Revenues per employee</b>   | 392,946     | 410,285     | 370,461     |

## Board of Directors

|                              |                             |
|------------------------------|-----------------------------|
| Iván López-Belmonte Encina   | Member of Supervisory Board |
| Javier López-Belmonte Encina | Member of Supervisory Board |
| Marcos Peña Pinto            | Member of Supervisory Board |
| Marina del Corral Téllez     | Member of Supervisory Board |
| María Fátima Báñez García    | Member of Supervisory Board |
| Teresa Santamaría            | Member of Supervisory Board |

## Members of Management Board

|                                       |                               |
|---------------------------------------|-------------------------------|
| Juan López-Belmonte Encina            | Chairman of Managing Board    |
| Aránzazu Lozano Pirrongelli           | Member of Executive Committee |
| Beatriz Avila Alcalde                 | Member of Executive Committee |
| Fernando Martínez Garjo               | Member of Executive Committee |
| Francisco Javier Ángulo García        | Member of Executive Committee |
| Gabriel Núñez Fernández               | Member of Executive Committee |
| Ibón Gutierro Adúriz                  | Member of Executive Committee |
| M. Rosario Perucha Perez              | Member of Executive Committee |
| Marta Campos Martínez                 | Member of Executive Committee |
| Mercedes Benitez del Castillo Sanchez | Member of Executive Committee |
| Miguel Angel Castillo Román           | Member of Executive Committee |